Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/14/2017 09/15/2017 09/18/2017 09/19/2017 09/20/2017 Date
53.14(c) 53.79(c) 52.89(c) 51.79(c) 52.84(c) Last
662 322 1 601 495 1 778 500 745 878 1 230 816 Volume
-0.49% +1.22% -1.67% -2.08% +2.03% Change
More quotes
Financials ($)
Sales 2017 445 M
EBIT 2017 -243 M
Net income 2017 -239 M
Finance 2017 444 M
Yield 2017 -
Sales 2018 576 M
EBIT 2018 -166 M
Net income 2018 -173 M
Finance 2018 315 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 16,0x
EV / Sales2018 12,6x
Capitalization 7 558 M
More Financials
Company
Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer.Its product ADCETRIS, is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent,... 
More about the company
Surperformance© ratings of Seattle Genetics, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on SEATTLE GENETICS, INC.
09/14 SEATTLE GENETICS : Stocks Under Scanner in the Biotech Space -- Puma Biotech, Re..
09/08 SEATTLE GENETICS : Highlights Promising Data with Tisotumab Vedotin in Cervical ..
09/07 GENMAB : and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors
09/06 SEATTLE GENETICS : to Present at Morgan Stanley Global Healthcare Conference
09/01 SEATTLE GENETICS, INC. : Today's Research Reports on Stocks to Watch: Seattle Ge..
08/29 SEATTLE GENETICS : Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin f..
08/24 SEATTLE GENETICS : FDA Accepts Supplemental Biologics License Application and Gr..
08/24 SEATTLE GENETICS : Unum Therapeutics Announces Active Investigational New Drug (..
08/17 SEATTLE GENETICS : Patent Issued for Methods for Screening Antibodies (USPTO 972..
08/17 BIOTECH MOVERS : Valeant Pharmaceuticals International, Inc. (NYSE:VRX), Aerie P..
More news
Sector news : Biotechnology & Medical Research - NEC
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/19$SGEN ALERT: New Seattle Genetics SEC Filing From our Stock News Alerts App 
09/19$SGEN - Somewhat Positive News Coverage Somewhat Unlikely to Impact Seattle G.. 
09/19Traders Buy Shares of Seattle Genetics, Inc. $SGEN on Weakness  
09/18Seattle Genetics, Inc. $SGEN Holdings Lifted by Verity Asset Management Inc. .. 
09/15$SGEN ALERT: New Seattle Genetics SEC Filing From our Stock News Alerts App 
More tweets
Qtime:32
News from SeekingAlpha
09/15 SEATTLE GENETICS : Good Time To Buy Based On Adcetris Label Expansion
09/15 Premarket analyst action - healthcare
08/29 Seattle Genetics and Genmab team up to develop ADC tisotumab vedotin
08/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 19, 2017
08/16 FDA accepts Seattle Genetics marketing application for Adcetris for CTCL, act..
Chart SEATTLE GENETICS, INC.
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | SGEN | US8125781026 | 4-Traders
Technical analysis trends SEATTLE GENETICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 58,6 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Eric L. Dobmeier Chief Operating Officer
Todd E. Simpson Chief Financial Officer
Jonathan Drachman Chief Medical Officer, EVP-Research & Development
Vaughn B. Himes Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
SEATTLE GENETICS, INC.-1.86%7 558
INCYTE CORPORATION16.77%24 665
QUINTILES IMS HOLDINGS INC24.22%20 435
LONZA GROUP54.86%19 892
CELLTRION, INC.--.--%15 174
ALKERMES PLC-6.41%7 766